• A comprehensive multi-scale in silico approach for predicting antibody-drug conjugate clinical efficacy across oncological indications

A Tailored In Silico approach for a Given Population and Indication can Effectively inform other Contexts of Use. As demonstrated by Extending an ADC in Silico Trial from Breast Cancer to Gastric Cancer in humans.

Download Poster

    Scroll to Top